Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

MANF publishes data in Molecular Neurobiology
March 2018
SHARING OPTIONS:

SAN FRANCISCO—MANF Therapeutics, the wholly owned subsidiary of Amarantus Bioscience Holdings Inc., recently published research detailing preclinical work related to mesencephalic astrocyte-derived neurotrophic factor (MANF), which the company is advancing for the treatment of orphan ophthalmological disorders, glaucoma and Parkinson’s disease. The paper in question, “Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) Elevates Stimulus-Evoked Release of Dopamine in Freely-Moving Rats,” was published in Molecular Neurobiology. One week following MANF treatment, an increased release of dopamine was seen in rat models as well as increased dopamine turnover in the rat striatum in response to stimulus. Existing approved drugs for Parkinson’s disease tend to target dopamine replacement, while disease-modifying drugs such as neurotrophic factors generally focus on rescuing dopaminergic neurons. A treatment such as MANF that could encapsulate both approaches could offer a much more effective option for Parkinson’s patients.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.